Pipeline of Myasthenia Gravis Reviewed for H2 2015

Mar 24, 2016, 22:00 ET from RnR Market Research

PUNE, India, March 25, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Myasthenia Gravis - Pipeline Review, H2 2015" to its store. The report provides an overview of the Myasthenia Gravis's therapeutic pipeline with comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects.

Complete report on H2 2015 pipeline review of Myasthenia Gravis with 30 market data tables and 13 figures, spread across 96 pages is available at http://www.rnrmarketresearch.com/myasthenia-gravis-pipeline-review-h2-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Myasthenia Gravis Pipeline Review, H2 2015 report include Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., CuraVac, Inc., Cytokinetics, Inc., GlaxoSmithKline Plc, Grifols, S.A., HanAll Biopharma Co., Ltd., Karus Therapeutics Limited, Neurotune AG, Pfizer Inc., Regenesance BV and Toleranzia AB. Drug profiles discussed in this research report includes amifampridine phosphate, belimumab, Coversin, CVMG-01, eculizumab, GL-2045, HL-161, immune globulin (human), KA-1463, NT-1654, Recombinant Protein for Myasthenia, Gravis, regenemab, Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis, tirasemtiv and Vaccine for Myasthenia Gravis.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=414334 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Myasthenia Gravis and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research report titled on Erectile Dysfunction - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Erectile Dysfunction Pipeline market research report of 113 pages is available at http://www.rnrmarketresearch.com/erectile-dysfunction-pipeline-review-h2-2015-market-report.html .

Explore more reports on Therapeutics .

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345


SOURCE RnR Market Research